Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The comp... Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. Mehr anzeigen
Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a...
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.171 | -17.6288659794 | 0.97 | 0.97 | 0.61 | 76286 | 0.78201237 | CS |
| 4 | -0.281 | -26.0185185185 | 1.08 | 1.125 | 0.61 | 115397 | 0.94909249 | CS |
| 12 | -0.161 | -16.7708333333 | 0.96 | 1.44 | 0.61 | 1260053 | 1.17138492 | CS |
| 26 | -1.201 | -60.05 | 2 | 4.55 | 0.61 | 1270010 | 2.01548694 | CS |
| 52 | -9.301 | -92.0891089109 | 10.1 | 12.36598 | 0.61 | 1032465 | 2.96471383 | CS |
| 156 | -87.601 | -99.0961538462 | 88.4 | 105.6 | 0.61 | 621792 | 9.65684105 | CS |
| 260 | -154.401 | -99.4851804124 | 155.2 | 486.8 | 0.61 | 642087 | 70.46378467 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
